AAN 2021 poster: Steroid switching in the treatment of dystrophinopathies in the US: A nationwide chart review of patient characteristics and clinical outcomes
This poster, from the 2021 virtual AAN meeting, presents findings of a review of real-world steroid switching in US patients with muscular dystrophies
Review the characteristics of patients with Becker muscular dystrophy (BMD) or Duchenne muscular dystrophy (DMD) who had switched steroid treatment and were included in this real-world study
Discover the physician-reported reasons for steroid switching – including desire to slow disease progression, tolerability issues, and patient/caregiver requests
Explore the clinical outcomes of steroid switching, as measured by Clinical Global Impression scores, alongside safety analyses
Deflazacort is a corticosteroid indicated for the treatment of DMD in patients 2 years of age and older. PTC Therapeutics is the Marketing Authorization Holder for deflazacort in the US only. Registration conditions differ internationally, and prescribing information may vary depending on local approval in each country. The US Prescribing Information for deflazacort is available here. Please refer to your local country guidance for more information.
Some cookies are essential, others help us improve your experience by providing insights into how the website is used. Select one or more of the cookie types listed below, and then save your preferences. Refer to our Cookies Statement for more information.
Performance cookies, which help us measure the website’s performance and improve your experience. In using performance cookies we do not store any personal data, and only use the information collected through these cookies in aggregated and anonymised form.